Hotgen(SH:688068) Xin Lang Cai Jing·2025-11-19 02:20Group 1 - The core point of the news is that 热景生物 (Hotgen Biotech) experienced a decline of 5.13% in its stock price, reaching 163.17 CNY per share, with a trading volume of 1.18 billion CNY and a market capitalization of 15.127 billion CNY [1] - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments. The revenue composition is as follows: testing reagents 70.87%, testing instruments 19.79%, others 8.17%, and biological raw materials 1.17% [1] Group 2 - 中航优选领航混合发起A (CASC Optimal Selection Mixed Fund A) has increased its holdings in Hotgen Biotech by 53,100 shares in the third quarter, bringing the total to 290,100 shares, which constitutes 11.14% of the fund's net value, making it the fourth-largest holding [2] - The fund has reported a floating loss of approximately 2.5616 million CNY as of the latest data [2] - The fund manager, 王森 (Wang Sen), has been in charge for 2 years and 55 days, with the fund's total asset size at 2.85 billion CNY. The best return during his tenure is 132.1%, while the worst return is -0.6% [3]